VVestlaw,
`
`4/13/04 CANCERWK 19
`
`NewsRoom
`
`Page 1
`
`4/13/04 Cancer Wkly. Plus 19
`2004 WLNR 542429
`
`Copyright 2004 Cancer Weekly via Newst.com & Newstnet
`
`Cancer Weekly
`
`April 13, 2004
`
`Section: Expanded Reporting
`
`European launch of Faslodex reported
`Breast Cancer
`
`AstraZeneca announced the first European launches of its new breast cancer drug Faslodex ( fulvestrant) in Germany
`
`and Sweden, with Austria following imminently.
`
`The novel drug - an estrogen receptor antagonist with no agonist effects - is for the treatment of advanced breast cancer
`
`in postmenopausal women whose cancer has progressed on previous anti-estrogen treatments such as tamoxifen.
`
`Fulvestrant has been launched in the US. since May 2002, and more recently in Brazil in July 2003.
`
`Fulvestrant was approved for launch in the European Union (EU) on 12 March 2004, making it the first new type of
`
`hormonal treatment for estrogen receptor-positive breast cancer to be approved in the EU. since 1995. The launch of
`
`the drug in Germany, Sweden, and Austria therefore provides new hope to the thousands of women suffering from
`
`advanced disease in these countries. Further launches throughout Europe are expected during the course of this year.
`
`Commenting on the launch, professor Kurt Possinger, head of the oncology department at Humboldt University of
`
`Berlin, Germany, explains, "The availability of 'Faslodex' in these countries is very exciting as women who have
`
`progressed on prior tamoxifen therapy now have a new additional and effective treatment option which may help
`
`extend the window of endocrine therapy and delay the use of cytotoxic chemotherapies with their well-recognized and
`unwanted side-effects.
`
`In addition, unlike other endocrine therapies used in postmenopausal women, 'Faslodex' is a once-monthly injection
`
`which enables clinicians to have greater contact with their patients to review progress and free women of the worry of
`
`remembering to take a daily tablet, allowing them to focus on their life and not their illness."
`
`Breast cancer affects one in nine women at some point in their lives and although many tumors are detected early and
`
`© 2015 Thomson Reuters. No Claim to Orig. US Gov. Works.
`
`AstraZeneca Exhibit 2067 p. l
`InnoPharrna Licensing LLC v. AstraZeneca AB lPR2017-00905
`
`

`

`4/13/04 CANCERWK 19
`
`Page 2
`
`treated successfully, a large number of women still go on to be diagnosed with advanced breast cancer. The goal of
`
`treatment for these women is to achieve an effective disease response and to enable the patient to maintain good
`
`quality of life for as long as is feasibly possible.
`
`Hormonal agents such as aromatase inhibitors and tamoxifen are standard therapy in postmenopausal women with
`
`advanced breast cancer, providing an effective and well-tolerated treatment option. However, in time tumour cells can
`
`grow resistant to treatment with these hormonal therapies and as a result there is a need for new agents to which tumors
`
`are not resistant. Fulvestrant is an exciting new type of therapy, which brings new choices for women with advanced
`
`disease, extending the sequence of 'patient-friendly' hormonal therapies that can be used to control the disease.
`
`Fulvestrant works differently to any other treatment available, although like the other hormonal therapies it interferes
`
`with the effect of the homione 'estrogen' 011 tumour growth. Many breast cancers are dependent on the presence of
`
`estrogen to grow. Of the current therapies, aromatase inhibitors (e. g. Arimidex (anastrozole)) work by reducing the
`
`amount of estrogen in a woman's body, and tamoxifen (an anti-estrogen) blocks estrogen receptors. However, ta-
`
`moxifen also mimics some of the actions of estrogen, which can result in unwanted side effects. In contrast, fulvestrant
`
`works by blocking and removing the estrogen receptors in the breast cancer cells and, unlike tamoxifen, does not
`
`mimic the actions of estrogen.
`
`Fulvestrant offers durable responses and has tolerability benefits compared with aromatase inhibitors and tamoxifen.
`
`Fulvestrant is effective following disease progression on prior anti-estrogen and aromatase inhibitor therapy in addi-
`
`tion both therapies are effective following fulvestrant therapy. Fulvestrant therefore meets a key unmet need for
`
`women with advanced breast cancer, since it can be added in to the sequence of well-tolerated hormonal therapies and
`
`may delay the need to resort to cytotoxic chemotherapies with their well-recognized side effects.
`
`This article was prepared by Cancer Weekly editors from staff and other reports. Copyright 2004, Cancer Weekly via
`Newst.com & Newstnet.
`
`Copyright © 2004 Cancer Weekly via Newst.com & Newst.net
`
`---- INDEX REFERENCES ---
`
`COMPANY: ASTRAZENECA PLC
`
`NEWS SUBJECT: (Health & Family (1HE30); World Organizations (lIN77); European Union (lEU94))
`
`INDUSTRY: (Pharmaceuticals & Biotechnology (1PH13); Healthcare (lHE06); Endocrinology & Metabolism
`
`(lEN72); Internal Medicine (lIN54); Healthcare Practice Specialties (1HE49); Cancer Dmgs (lCA2l); Oncology &
`
`Hematology (lON95))
`
`REGION: (Western Europe (lWE4 1); Austria (1AU3 9); Scandinavia (lSC27); Germany (lGEl6); Europe (1EU83);
`
`Northern Europe (lNOO 1); Central Europe (lCE50))
`
`© 2015 Thomson Reuters. No Claim to Orig. US Gov. Works.
`
`AstraZeneca Exhibit 2067 p. 2
`
`

`

`4/13/04 CANCERWK 19
`
`Page 3
`
`Language: EN
`
`OTHER INDEXING: (ASTRAZENECA; EUROPEAN UNION; HUMBOLDT UNIVERSITY) (An'midex; Breast
`
`Cancer; Cancer Weekly; Commenting; Faslodex; Kurt Possinger)
`
`KEYWORDS: AstraZeneca; Therapy; Women's Health; All News; Consumer News; Oncology
`
`Word Count: 841
`
`4/13/04 CANCERWK l9
`
`END OF DOCUMENT
`
`© 2015 Thomson Reuters. No Claim to On'g. US Gov. Works.
`
`AstraZeneca Exhibit 2067 p. 3
`
`